VivoSeq
Oncology

Advanced Solid Tumors

23

Pipeline Programs↗

375

Active Trials↗

248

Companies Involved↗

Advanced Solid Tumors is an emerging landscape with 23 programs across 248 companies. The most active players are Merck & Co., Bayer, Pheast Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

87/100

Mech. Concentration

33/100

Completion Rate

68/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 1Bayer logo

Bayer

2 programs

Phase 1P

Pheast Therapeutics

2 programs

Phase 1Roche logo

Roche

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

16 of 22 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody523%RNA therapy15%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 76% of 29 pipeline programs.

Analysis

Trial Status

959

clinical trials

Completed332 · 35%
Recruiting256 · 27%
Terminated142 · 15%
Unknown status91 · 9%
Active, not recruiting60 · 6%
Not yet recruiting58 · 6%
Other20 · 2%

Clinical Trials

Trial Activity

959 trials

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Recruiting·SShanghai Yunying Medical Technology·Phase 1·NCT05961111·20 enrolled
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Recruiting·MMemgen, Inc.·Phase 1·NCT05076760·40 enrolled
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Recruiting·NNextCure, Inc.·Phase 1·NCT06792552·414 enrolled
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 1·NCT06644755·150 enrolled
ARC101 in Advanced Solid Tumors
Recruiting·TThird Arc Bio·Phase 1·NCT06672185·70 enrolled
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Recruiting·AAnkyra Therapeutics, Inc·Phase 1·NCT06171750·97 enrolled
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors
Recruiting·GGrit Biotechnology·Phase 1·NCT05430360·30 enrolled
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruiting·AAptabio Therapeutics, Inc.·Phase 1·NCT07123415·110 enrolled
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Recruiting·GGuangzhou FineImmune Biotechnology Co., LTD.·Phase 1·NCT03891706·30 enrolled
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Recruiting·BBroadenbio Ltd., Co.·Phase 1·NCT06258408·78 enrolled
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Recruiting·GGuangzhou FineImmune Biotechnology Co., LTD.·Phase 1·NCT06302062·23 enrolled
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
Recruiting·HHangzhou Converd Co., Ltd.·N/A·NCT07185243·24 enrolled
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT07134998·153 enrolled
c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration
Recruiting·YYonsei University·Phase 2·NCT05882292·20 enrolled
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Recruiting·EExelixis·Phase 1·NCT05932862·429 enrolled
Page 1 of 64

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)